Overview
Israel biotechnology firm's 2025 net loss widened, with increased R&D and admin expenses
Company advanced PrimeC into late-stage clinical development with FDA-cleared Phase 3 ALS trial
Statistically significant survival benefit reported for PrimeC, including 65% reduction in risk of death
Outlook
Company expects additional biomarker readouts from PARADIGM and Phase 2 Alzheimers study in 2026
NeuroSense plans pre-NDS meeting with Health Canada in May 2026 and potential NDS submission
Company continues preparing for initiation of Phase 3 PARAGON trial in ALS
Result Drivers
INCREASED R&D SPENDING - Higher research and development expenses mainly due to increased share-based payment expenses and higher salaries, partly offset by lower subcontractor costs
ADMIN COSTS - General and administrative expenses rose due to higher share-based compensation
Company press release: ID:nPn4J9TsNa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY EPS | -$0.44 | ||
FY Operating Income | -$11.09 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Neurosense Therapeutics Ltd is $8.25, about 1,028.6% above its March 30 closing price of $0.73
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
